Login to Your Account

Will ESA Spectre Haunt Affymax Anemia Drug?

By Mari Serebrov
Washington Editor

Tuesday, December 6, 2011
The ghost of anemia drugs present could haunt Affymax Inc.'s peginesatide injection when it comes up for discussion Wednesday at a meeting of the FDA's Oncologic Drugs Advisory Committee (ODAC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription